|
Re: Trading strategy
|
6
|
Resverlogix Corp.
|
Sep 22, 2019 04:11PM
|
|
Re: BIO-Europe Presentation
|
6
|
Zenith Epigenetics
|
Mar 13, 2018 04:05PM
|
|
Re: Two slots remain TBA....
|
6
|
Resverlogix Corp.
|
Feb 17, 2020 02:58PM
|
|
Re: AE/LFT concerns
|
6
|
Resverlogix Corp.
|
Nov 16, 2019 06:56PM
|
|
Re: Who's on twitter?
|
6
|
Resverlogix Corp.
|
Dec 06, 2019 09:34AM
|
|
New MD&A posted
|
6
|
Resverlogix Corp.
|
Dec 17, 2019 06:56AM
|
|
Re: Zenith Updates
|
6
|
Zenith Epigenetics
|
Feb 02, 2016 10:41PM
|
|
Re: Apabetalone......a Calculated Risk
|
6
|
Resverlogix Corp.
|
Apr 09, 2019 07:23PM
|
|
Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes
|
6
|
Resverlogix Corp.
|
May 08, 2020 02:20PM
|
|
Re: New patent
|
6
|
Resverlogix Corp.
|
Nov 03, 2019 08:48AM
|
|
Re: Q1 Webcast
|
6
|
Resverlogix Corp.
|
Feb 02, 2016 10:44PM
|
|
Apabetalone downregulates factors and pathways associated with vascular calcification
|
6
|
Resverlogix Corp.
|
Nov 20, 2018 10:37AM
|
|
Re: Japanese publication response from IR
|
6
|
Zenith Epigenetics
|
Nov 01, 2016 02:09PM
|
|
2019 Annual and Special Meeting of Shareholders and Webcast of Corporate Update
|
6
|
Zenith Epigenetics
|
Oct 30, 2019 11:24AM
|
|
Re: DSMB and SSRA
|
6
|
Resverlogix Corp.
|
Aug 07, 2018 02:27PM
|
|
Re: time to add/3 vs 5 pt. MACE
|
6
|
Resverlogix Corp.
|
Mar 21, 2018 11:47AM
|
|
Re: Fierce Biotech BET inhibitor/PD-L1 cancer article
|
6
|
Zenith Epigenetics
|
Sep 15, 2016 04:44PM
|
|
Bromodomain-2 Selective BET inhibitors
|
6
|
Resverlogix Corp.
|
Apr 19, 2018 10:35AM
|
|
Re: Bringing us back on track
|
6
|
Resverlogix Corp.
|
Feb 29, 2020 09:59PM
|
|
Re: Coronary Artery Calcium Score
|
6
|
Resverlogix Corp.
|
Feb 18, 2019 05:14PM
|
